Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

PROGRAM SUPPORT CENTER ACQ MGMT SVC

Contract Value

Not provided

Codes & Classification
Solicitation Number

NIH-26-006363-IntentNotice

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

6550

Additional Details
Set Aside

NONE

Place of Performance

Philadelphia, Pennsylvania, UNITED STATES

SourceSAM
This presolicitation notice announces the intent of the Department of Health and Human Services, specifically the Office of the Assistant Secretary for Administration (ASA), to award a sole source contract for nucleic acid–based reagents intended for in vivo transient protein expression. The contract will be awarded to the Trustees of The University of Pennsylvania - Penn Medicine, located at 3451 Walnut Street, Philadelphia, PA 19104, USA. The procurement is managed by the Program Support Center Acquisition Management Service, with Ivan Mora-Juarez as the primary point of contact ([email protected], 301-443-0055). The primary purpose of this procurement is to support ongoing research at the National Cancer Institute and the Center for Cancer Research. The nucleic acid-based reagents are critical for investigating preventive strategies against viral infections, specifically HIV/Simian Immunodeficiency Virus (SIV) and Human T-lymphotropic Virus (HTLV), in preclinical models. These reagents are designed to express viral antigens, enabling their use as preventive treatments in experimental settings. The intended outcome is to further the development of effective countermeasures by evaluating the ability of these reagents to induce protective immune responses and confer protection against target pathogens. A key objective of this procurement is to ensure experimental consistency and data integrity. The nucleic acid-based reagents have been used in prior preclinical studies conducted by the AMRVS, demonstrating their efficacy and safety as preventive countermeasures. To maintain continuity with previous research and enable direct comparison of results, it is essential to source these reagents from the same supplier. Variations in formulation, synthesis methods, or purity from different suppliers could introduce inconsistencies, potentially complicating data interpretation and undermining reproducibility. Therefore, the use of the same supplier is justified to support the reliability and validity of ongoing and future studies. The scope of the contract encompasses the supply of nucleic acid-based reagents with broad activity against various viral subtypes, including those associated with cancer induction. The deliverables are expected to meet the standards established in previous studies, ensuring compatibility with existing experimental protocols and data sets. This procurement is classified under NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing) and Product Service Code 6550. There are no set-aside requirements associated with this opportunity, and it is not open for competitive quotations or capability statements. The place of performance is Philadelphia, Pennsylvania. Contractors should note that this notice is for informational purposes only and does not constitute a request for competitive proposals. No inquiries or questions regarding this presolicitation will be entertained. The notice remains active, with a response date set for February 14, 2026. For further details, interested parties may refer to the official posting on SAM.gov (Opportunity ID: 16f0d3a0ac4244809319904e2656f3c7).